STAT2d
Novo Nordisk follows Eli Lilly with its own ‘triple-G’ drug
Novo Nordisk said yesterday that it’s licensed a new obesity drug from The United Laboratories, a Chinese drugmaker.
Fierce Biotech3d
Novo Nordisk pens $2B deal for triple G agonist tied to 15% weight loss at 12 weeks
Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...
The Manhattan Mercury2d
Novo Nordisk To Pay $2 Billion for New Weight Loss Drug
Novo Nordisk will pay $200 million up front, with up to $1.8 billion in additional payments down the line, The Wall Street ...
Blockbuster weight-loss drug Mounjaro comes to India: How does it work?
The popular anti-obesity drug Mounjaro has finally been launched in India. The development comes after Eli Lilly received ...
Eli Lilly’s weight loss drug launches in India: Here are 4 things to know about Mounjaro
The new class of weight-loss medicines that has taken the world by a storm will now become available in India, with the ...
Mounjaro hits shelves in India: How Eli Lilly’s weight loss drug compares with Ozempic — price, side effects and more
Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and ...
Indiatimes6d
Mounjaro: As Eli Lilly's blockbuster anti-obesity drug comes to India, expert lists key side effects
Eli Lilly has launched Mounjaro ... activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.
The New Indian Express7d
Eli Lilly launches weight-loss drug Mounjaro in India at competitive pricing
NEW DELHI: US-based pharmaceutical giant Eli Lilly has launched its blockbuster ... dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors, making it a ...